Have a feature idea you'd love to see implemented?
Let us know!
HOOK HOOKIPA Pharma Inc
Price (delayed)
$2.3
Market cap
$27.73M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.72
Enterprise value
-$29.2M
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that reprograms the body's immune system.
Highlights
The EPS has soared by 55% YoY and by 14% from the previous quarter
The debt has declined by 42% since the previous quarter and by 27% year-on-year
The revenue has soared by 143% YoY but it has decreased by 4.1% QoQ
HOOKIPA Pharma's gross profit has surged by 143% YoY but it has decreased by 4.1% QoQ
The company's equity fell by 24% YoY and by 17% QoQ
HOOK's quick ratio is down by 17% from the previous quarter and by 8% YoY
Key stats
What are the main financial stats of HOOK
Market
Valuations
Earnings
Shares outstanding
12.05M
Market cap
$27.73M
Enterprise value
-$29.2M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.39
Price to sales (P/S)
0.55
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.58
Revenue
$50M
EBIT
-$43.16M
EBITDA
-$39.82M
Free cash flow
-$67.88M
Per share
Balance sheet
Liquidity
EPS
-$3.72
Free cash flow per share
-$5.63
Book value per share
$5.96
Revenue per share
$4.15
TBVPS
$9.1
Total assets
$109.73M
Total liabilities
$37.93M
Debt
$2.83M
Equity
$71.8M
Working capital
$64.59M
Debt to equity
0.04
Current ratio
3.26
Quick ratio
2.97
Net debt/EBITDA
1.43
Margins
Efficiency
Dividend
EBITDA margin
-79.6%
Gross margin
100%
Net margin
-86.7%
Operating margin
-121.8%
Return on assets
-32%
Return on equity
-49.3%
Return on invested capital
-196.8%
Return on capital employed
-53.2%
Return on sales
-86.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
HOOK stock price
How has the HOOKIPA Pharma stock price performed over time
Intraday
-15.44%
1 week
-26.75%
1 month
-42.36%
1 year
-50%
YTD
-71.6%
QTD
-46.51%
Financial performance
How have HOOKIPA Pharma's revenue and profit performed over time
Revenue
$50M
Gross profit
$50M
Operating income
-$60.89M
Net income
-$43.37M
Gross margin
100%
Net margin
-86.7%
The revenue has soared by 143% YoY but it has decreased by 4.1% QoQ
HOOKIPA Pharma's gross profit has surged by 143% YoY but it has decreased by 4.1% QoQ
The net margin has surged by 74% year-on-year and by 7% since the previous quarter
The operating margin has surged by 69% year-on-year and by 2.2% since the previous quarter
Growth
What is HOOKIPA Pharma's growth rate over time
Valuation
What is HOOKIPA Pharma stock price valuation
P/E
N/A
P/B
0.39
P/S
0.55
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.58
The EPS has soared by 55% YoY and by 14% from the previous quarter
The P/B is 70% below the 5-year quarterly average of 1.3 and 44% below the last 4 quarters average of 0.7
The company's equity fell by 24% YoY and by 17% QoQ
The revenue has soared by 143% YoY but it has decreased by 4.1% QoQ
The price to sales (P/S) is 93% lower than the 5-year quarterly average of 8.4 and 68% lower than the last 4 quarters average of 1.7
Efficiency
How efficient is HOOKIPA Pharma business performance
The ROS has soared by 74% YoY and by 7% from the previous quarter
The company's return on invested capital rose by 45% YoY and by 15% QoQ
HOOKIPA Pharma's return on equity has increased by 30% YoY and by 4.8% QoQ
The ROA is up by 20% YoY
Dividends
What is HOOK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for HOOK.
Financial health
How did HOOKIPA Pharma financials performed over time
The total assets is 189% more than the total liabilities
The total liabilities has declined by 45% year-on-year and by 2.7% since the previous quarter
The total assets has contracted by 33% YoY and by 12% from the previous quarter
The debt is 96% smaller than the equity
The debt has declined by 42% since the previous quarter and by 27% year-on-year
HOOKIPA Pharma's debt to equity has decreased by 33% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.